

# TGEX-HC-hG1[EA]-Zeo

Mammalian Expression Vector for Fc-Engineered Constant Region of Human IgG1 Heavy Chain

Catalog #: MX041

Version: A1.5 – October 2023

*For Research Use Only*

## Product Information

**Contents:** 10 µg of TGEX-HC-hG1[EA]-Zeo plasmid in 20 µl of DNA Conservation Buffer (5 mM Tris-HCl, 0.1 mM EDTA, pH 8.5) (0.5 µg/µl).

**Storage:** The plasmid is shipped on ice. Upon receipt, store at the plasmid at -20°C.

**Quality control:** The plasmid was confirmed by sequencing and certified to meet all specifications.

## General Product Use

The **TGEX™** vector series is designed for the rapid expression of antibody molecules by transient gene expression in mammalian cells in suspension culture. Transfection of **TGEX™** expression vectors harboring variable region inserts typically yields antibody titers between 50 – 250 mg/L in serum-free conditions in just a few days.


**TGEX™-HC** family vectors are designed for the expression of an antibody heavy chain variable region with the constant heavy region of an isotype of choice (**Antibody Design Labs** offers many different isotypes in both wild-type and engineered forms, see **Related Products**). Expression of full-length antibodies is achieved with co-transfection with a light chain variable region cloned in to one of the **TGEX™-LC** family vectors.

**Antibody Design Labs** provides a variety of engineered **TGEX™-HC-hG** vectors, which are designed to express human heavy chains with specific amino acid substitutions in their constant region known to modulate antibody half-life or increase/decrease antibody effector functions (i.e., antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)).

## References

1. Logan J., & Shenk T. 1984. Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. *Proc Natl Acad Sci*, 81(12):3655–9.
2. Mariati, H. et al. 2010. Evaluating post-transcriptional regulatory elements for enhancing transient gene expression levels in CHO K1 and HEK293 cells. *Protein Expr Purif*, 69(1):9–15.
3. Valadon P. et al. 2006. Screening phage display libraries for organ-specific vascular immunotargeting in vivo. *Proc Natl Acad Sci*, 103(2):407–12.
4. Lin-Chao S. et al. 1992. High copy number of the PUC plasmid results from a ROM/ROP-suppressible point mutation in RNA II. *Mol Microbiol*, 6(22):3385–93.
5. Idusogie E. et al. 2001. Engineered Antibodies with Increased Activity to Recruit Complement. *J Immunol*, 166 (4): 2571–2575.

## Plasmid Features



- ❖ **CMV promoter and adenovirus tripartite leader sequence<sup>1,2</sup>** for enhanced expression and translation of transgenes.
- ❖ **Composite pelBK leader<sup>3</sup>:** a hybrid between mammalian kappa leader and bacterial leader for secretion of the immunoglobulin chain.
- ❖ Double-inverted **BsaI cloning site** optimized for homologous recombination using **FAST-Licase™** (Catalog #: MB101S, MB101L) or restriction enzyme cloning.
- ❖ **IRES** sequence for efficient co-expression of selective marker using the same promoter.
- ❖ **Zeo:** *Sh ble* gene from *Streptoalloteichus hindustanus* conferring resistance to Zeocin™ for selection of stable transformants in mammalian cell lines.
- ❖ **WPR:** Woodchuck hepatitis post-transcriptional regulatory element for enhanced expression of transgenes.
- ❖ **BGPA:** Rabbit β-globin polyadenylation signal for efficient polyadenylation.
- ❖ **pMB1:** Origin of replication for *E. coli* with a temperature-sensitive high copy-number phenotype.<sup>4</sup>
- ❖ **AmpR:** TEM1 β-lactamase gene conferring resistance to ampicillin for selection in *E. coli*.

## Specific Features

- ❖ **HC-hG1[EA]:** human IgG1 heavy chain constant region with an E333A mutation in the CH2 domain known to increase ADCC and CDC *in vitro*.<sup>5</sup>

---

## Protocol

---

### Cloning Into TGEX™-HC-hG Vectors

A double-inverted BsaI cloning site separates the pelBK leader peptide sequence from the beginning of the antibody constant region. Cloning into a BsaI-digested TGEX™ vector may be accomplished by two different methods (see below). Both methods result in removal of BsaI sites, which results in the scarless insertion of the antibody variable domain into the plasmid.

#### Homologous Recombination (Preferred Method):

Homologous recombination is the easiest and most efficient method to seamlessly clone antibody variable regions into TGEX™ vectors. We recommend the **FAST-LICASE™** (Catalog #: MB101S, MB101L) with the following overhangs:

**pelBK overhang** 5' – CGGCCAGCCGGCCATGGCA

**hlgG1 overhang** 5' – GCATCCACCAAGGGCCATC  
(reverse complement for PCR primers)

For synthetic dsDNA constructs, the overhangs are added to each side of the VH domain. For PCR-amplified constructs, primers should contain the overhang followed by the antibody variable region priming area, see **FAST-LICASE™** manual for additional details.

#### Restriction Cloning (Alternative Method):

Antibody variable regions can be cloned into TGEX™ vectors by restriction cloning by designing primers to amplify variable regions with the required BsaI sites with sufficient complementarity overhangs for in-frame ligation, see examples of compatible oligos below:

**Oligo1** 5' –NNGGTCTCTGGCA–VH–start

**Oligo2** 5' –NNGGTCTCGATGC–JH–end

If the antibody variable region insert contains BsaI sites, which prevents cloning using this method, the BsaI sites can be replaced with sites for another type IIS restriction enzyme that generates identical 4-base long 5' overhangs (e.g., BsmBI).

### Recombinant Antibody Production & Purification

Commonly used cell lines (e.g., HEK293, CHO) adapted for culture in suspension and serum-free conditions are recommended. Many transfection reagents designed for transient transfection are commercially available.

We recommend testing transfections conditions with a fluorescent reporter plasmid first (i.e., **TGEX™-eGFP-Zeo**, Cat# MX022) to evaluate transfection efficiency and determine optimal transfection conditions.

Expression of full-length antibodies requires cotransfection with heavy chain (i.e., **TGEX™-HC** family) and light chain (i.e., **TGEX™-LC**) vectors containing variable regions of interest. We recommend starting with a 1:1 light chain to heavy chain ratio during transfection. In our experience, a 2:1 light chain to heavy chain ratio often exhibits an increased expression, although each antibody may require fine tuning of the ratio for optimal expression.

Stably-transfected cells can be produced by selection using Zeocin™. We recommend culturing transfected cells for 6 days before supplementing growth media with 100 µg/ml Zeocin™. Continue passaging cells at regular intervals and densities while maintaining Zeocin™ concentration for an additional 2-3 weeks before increasing selective pressure to up to 1 mg/ml Zeocin™ for an additional 1-2 weeks. Following selection, proceed to single-cell subcloning and analysis of stable transformants for antibody expression.

Antibody production may be assessed by SDS-PAGE, ELISA, or another quantitative assay. Recombinant antibodies may be purified directly from culture supernatant using Protein A/G/L affinity chromatography or coated magnetic beads.

---

## Legal and Disclaimers

---

**Antibody Design Labs** grants to the buyer with the sale of its vectors (the "Product") a non-exclusive, non-transferable, royalty-free, commercial license to use Product in research conducted by the buyer (whether the buyer is an academic or a for-profit entity). The buyer is NOT granted a license to (a) use Product for human or animal therapeutic, diagnostic, or prophylactic purposes, (b) act as reseller or distributor of Product, or (c) resell, distribute, or transfer Product without modification under any name. **Antibody Design Labs** does not warrant that the use or sale of Product, the use thereof in combination with other products, or the use of Product in the operation of any process will not infringe the claims of any United States or other patent(s). If the buyer is not willing to accept the limitations of this license, without modification, buyer may refuse this license by returning Product unopened and unused. By keeping or using Product, buyer agrees to be bound by the terms of this license.

## Related Products

VECTOR	CATALOG	ISOTYPE/USE	DESCRIPTION
<b>Antibody Heavy Chain Expression Vectors</b>			
TGEX™-HC-hG1-Zeo	MX026	Human IgG1	Heavy chain expression plasmid for human IgG1
TGEX™-FH-hG1-Zeo	MX023	Human IgG1 CH1	Expression plasmid for human IgG1 Fab fragments
TGEX™-FC-hG1-Zeo	MX025	Human IgG1 Fc	Expression plasmid for human IgG1 Fc fusions
TGEX™-HC-hG2-Zeo	MX027	Human IgG2	Heavy chain expression plasmid for human IgG2
TGEX™-HC-hG3-Zeo	MX028	Human IgG3	Heavy chain expression plasmid for human IgG3
TGEX™-HC-hG4[S228P]-Zeo	MX029	Human IgG4[S228P]	Heavy chain expression plasmid for human IgG4
TGEX™-HC-mG1-Zeo	MX032	Murine IgG1	Heavy chain expression plasmid for murine IgG1
TGEX™-HC-mG2a-Zeo	MX033	Murine IgG2a	Heavy chain expression plasmid for murine IgG2a
TGEX™-HC-mG2b-Zeo	MX034	Murine IgG2b	Heavy chain expression plasmid for murine IgG2b
TGEX™-HC-mG3-Zeo	MX035	Murine IgG3	Heavy chain expression plasmid for murine IgG3
TGEX™-HC-rbG-Zeo	MX039	Rabbit IgG	Heavy chain expression plasmid for rabbit IgG
<b>Fc-engineered Antibody Heavy Chain Expression Vectors</b>			
TGEX™-HC-hG1[EA]-Zeo	MX041	Human IgG1	IgG1 heavy chain with mutated Fc to increase ADCC/CDC
TGEX™-HC-hG1[NA]-Zeo	MX042	Human IgG1	IgG1 heavy chain with mutated Fc for aglycosylated antibody
TGEX™-HC-hG1[LALA-PG]-Zeo	MX043	Human IgG1	IgG1 heavy chain with mutated Fc to reduce ADCC/CDC
TGEX™-HC-hG1[YTE-KF]-Zeo	MX044	Human IgG1	IgG1 heavy chain with mutated Fc to increase serum half-life
TGEX™-HC-hG4[SPLE-PG]-Zeo	MX045	Human IgG4[S228P]	IgG4 heavy chain with mutated Fc to reduce ADCC/CDC
<b>Antibody Light Chain Expression Vectors</b>			
TGEX™-LC-hK-Zeo	MX030	Human Kappa	Light chain expression plasmid for human Kappa
TGEX™-LC-hL-Zeo	MX031	Human Lambda 2	Light chain expression plasmid for human Lambda 2
TGEX™-LC-mK-Zeo	MX036	Murine Kappa	Light chain expression plasmid for murine Kappa
TGEX™-LC-mL1-Zeo	MX037	Murine Lambda 1	Light chain expression plasmid for murine Lambda 1
TGEX™-LC-mL2-Zeo	MX038	Murine Lambda 2	Light chain expression plasmid for murine Lambda 2
TGEX™-LC-rbKb4	MX040	Rabbit Kappa b4	Light chain expression plasmid for rabbit Kappa b4
<b>Engineering Vectors</b>			
TGEX™-AC-Zeo	MX020	Any expressions	Universal mammalian expression vector
TGEX™-eGFP-Zeo	MX022	Transfection control	Control plasmid for monitoring transient transfections
TGEX™-SCblue-Zeo	MX024	scFv cloning vector	For the transfer of scFv from any pADL phagemid vector and expression as scFv-Fc fusion

## Examples for Desired Antibody Format

COMBINATION	FORMAT	PURIFICATION METHOD <sup>1</sup>
TGEX™-HC-hG1-Zeo + TGEX™-LC-hK-Zeo	Full-length human or chimeric IgG1/K	Protein A or G
TGEX™-FH-hG1-Zeo + TGEX™-LC-hK-Zeo	Human or chimeric IgG1/K Fab fragment	Protein L, G or IMAC
TGEX™-FC-hG1	Human IgG1 Fc fusion	Protein A or G
TGEX™-SCblue-Zeo	Human IgG1 scFv-Fc fusion	Protein A or G

<sup>1</sup>Purification by Protein A, G, and L may require additional testing.

**SpeI (19)** AseI (27)  
 1 gttgacattgattattgactagttatataatagtaatacaattacggggcattagttcatagcccatatattggagttccgcgttacataacttacggtaaatggcc  
 106 cgctggctgaccgcccacgacccccgccattgacgtcaataatgacgtatgttcccataagtaacgccaatagggactttccattgacgtcaatgggtggagtt  
 211 atttacggtaaaactgcccacttggcagtagacatcaagtgtatcatatgccaaagtcgccccctattgacgtcaatgacggtaaatggccccgctggcattatgccc  
 316 agtagatgaccttacgggactttcctacttggcagtagacatctacgtattagtcacgtctattaccatgggtgatgcggttttggcagtagaccaatggcggtggat  
 421 agcggtttgactcacggggattttccaagtctccaccccatgacgtcaatgggagttgttttggcaccaaaatcaacgggactttccaaaatgctgtaataaac  
 526 ccgccccgttgacgcaaatggcggtgagcgtgtacgggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcctcactctctccgcacatcgctg  
 631 tctgaggggacagctgttggggtgagtagctccctctcaaaagggcgatgacttctgcgctaagattgtcagtttccaaaagcagagggatttgatattcacc  
 736 tggcccgcggtgatgcctttgaggggtggccgctccatctggtcagaaaaagacaatcttcccttgatgatgtcatacttatcctgtccctttttttccacagct  
 841 cgcggttgagacaaaactcttccggctcttccagtagctcttggatcggaaaaccgctcgccctccgaacggtagctccgccaccgagggacctgagcaggtccgca  
 946 tcgaccggatcggaaaacctctcagaaaagcgtctaacagtcacagtcgcaagtttaaacggatctctagcgaattcggcttggccgccaccatggagacag  
 1051 acacactcctgctatgggtactgctgctcttagcggcccagccggccatggcag**gagacctaacgcgtatggtctca**gcacccaccaagggcccatcggtcttcc  
 11 **L A P S S K S T S G G T A A L G C L V K D Y F P E P V T V S W N S G A**  
 1156 ccctggcaccctcctccaagagaccctctggggcaacagcggcctgggctgctggtcaaggactactccccgaaccggtagcgtgtcgtggaactcagggc  
 46 **L T S G V H T F P A V L Q S S G L Y S L S S V V T V P S S S L G T Q T**  
 1261 ccctgaccagcggcgtgcacaccttccggctgctctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggacccaga  
 81 **Y I C N V N H K P S N T K V D K K V E P K S C D K T H T C P P C P A P**  
 1366 cctacatctgcaacgtgaatcacaagcccagcaacccaaggtggacaagaaagttgagccaaatcttgtgacaaaactcacacatgccaccgctgccagcagc  
 116 **E L L G G P S V F L F P P K P K D T L M I S R T P E V T C V V V D V S**  
 1471 ctgaaactcctgggggaccgtcagctcttctcttccccccaaaacccaaggaaccctcatgatctcccggaaccctgaggtgcacatgctggtggtggagcgtga  
 151 **H E D P E V K F N W Y V D G V E V H N A K T K P R E E Q Y N S T Y R V**  
 1576 gccacgaagaccctgaggtcaagttcaactggtacgtggcagcggcgtggaggtgcataatgccaagacaaagccgaggagcagtagacaacagcagcgtaccgtg  
 186 **V S V L T V L H Q D W L N G K E Y K C K V S N K A L P A P I A K T I S**  
 1681 tggtagcagctcctcaccgtcctgcaccaggaactggctgaatggcaaggagtagaagtgcaaggtgtccaacaaagccctcccagccccatcgccgaaaacctct  
 221 **K A K G Q P R E P Q V Y T L P P S R D E L T K N Q V S L T C L L V K G F**  
 1786 ccaagccaaagggcagccccagagaaccacaggtgtacacctgcccccatcccggtgagctgaccaagaaccaggtcagcctgacctgctcgtggtcaaaagct  
 256 **Y P S D I A V E W E S N G Q P E N N Y K T T P P V L D S D G S F F L Y**  
 1891 tctatcccagcgacatcgccgtggagtgaggagcaatgggcagcgggagaacaactacaagaccagcctcccgtgctggactccgacggctccttctcctct  
 291 **S K L T V D K S R W Q Q G N V F S C S V M H E A L H N H Y T Q K S L S**  
 1996 atagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggtctgcacaaccactacacgcagagaagcctct  
 326 **L S P G K \*** NheI (2125)  
 2101 ccctgtctccgggtaataaaacagctagcgggttccaaacctgggttccccctctcccttccccccctaacgttactggccgaagccgcttggaaataaggccggtg  
 2206 tgcggttgctatattgtttttccaccatattgcccgtcttttggcaatgtgaggcccggaacacctggccctgtcttcttgacgagcattcctaggggtcttcc  
 2311 ccctctcgccaaaggaatgcaaggtctgttgaatgctgtaggaagagcagttcctctggagcttcttgaagacaaacagctctgtagcgacctttgacaggca  
 2416 gcggaaacccccacctggcgacaggtgcctctcgcccaaaaagccagctgtataagatacacctgcaaaagggcacaacccagtcgacagctgtgagttggat  
 2521 agttgtgaaagagtcacaatggctctcctcaagcgtattcaacaaggggctgaaggatgccagaaggtaccaccattgtatgggactctgctgggacctcggtg  
 2626 cacatgctttacatgtgttagtcaggggttaaaaaacgtctaggccccccgaaccacggggcagctggttttctcttgaaaaaacacgatgataagcttgccacaa  
 2731 cccgggatcctctagagtcgacatggccaagttgaccagtgccgttccgggtctcaccgcgcgagcgtcgccggagcggctcaggttctggaaccgacggctcgg  
 28 **F S R D F V E D D F A G V V R D D V T L F I S A V Q D Q V V P D N T L**  
 2836 gttctcccgggacttctgtaggagcagctctcggctgtggtccgggacagctgacctgttcatcagcgcggtccagacacaggttgggtccgggacaaacct  
 64 **A W V W V R G L D E L Y A E W S E V V S T N F R D A S G P A M T E I G**  
 2941 ggcctgggtgtgggtgcggcctggacgagctgtacggcagtggttcggaggtcgtgtccacgaacttccgggacgcctccgggcccggccatgaccgagatcgg

EagI (3085) EagI (3130)

100 **E Q P W G R E F A L R D P A G N C V H F V A E E Q D \*** **NotI (3130)**

3046 cgagcagcgtggggcgagggttcgccctgcgcgacccggccggcaactgctgcaactttgtggcagaggagcaggactgacgggccgcaatcaacctctggat

3151 tacaaaaatttgtaaagattgactgggtattcttaactatgttgctccttttacgctatgtggatagcctgctttaatgcctttgatcatgctattgcttcccg

3256 atggctttcattttctcctcctgtataaaatcctgggtgctgtctctttatgaggagttgtggcccggtgtcaggcaacgtggcggtgtgcaactgtgtttgt

3361 gacgcaacccccactggttggggcattgcccaccctgtcagctcctttccgggactttcgtcttccccctcctattgccacggcggaactcatcgccgctg

3466 cttgcccgctgctggacaggggctcggtgttgggcaactgacaattccgtggtgtgtcggggaagctgacgtcctttccatggctgctcgctgtgttgcacc

3571 tggattctgcgcgggagctcctctctgctacgtcccttcggccctcaatccagcggacctccttcccgcgctgctgcccgtctctgcggcctcttcccgctt

3676 cgcttcgcccctcagacgagtcggatctcctttggggcgcctccccgcagatccccgcacctcgacctctggctaataaaggaaattttttcattgcaatg

NdeI (3819) HindIII (3862)

3781 tgtgttggaaattttttgtgtctctcactcgaaagacatatggggaggcaaatcatttggctgagatccctcggagatctaagcttcatgtgagcaaaaggccag

3886 caaaaggccaggaaccgtaaaaaggccgcttctgtgctgtttttccataggtccgccccctgacgagcatcaaaaaatcgacgctcaagtcaaggtggcga

3991 aaccgacaggaactataaagataaccaggcgtttccccctggaagctccctcgtgctctcctgttccgacctgcccgttacccgatacctgtccgctttctc

4096 cttcgggaagcgtggcgctttctcatagctcagctgtaggtatctcagttccggtgtaggtcgctcctcaagctgggctgtgtgcaaccccccgcttccg

4201 cccgaccgctgccccttatccggtaactatcgtcttgagtcacaaccggtaagacacgacttatcgccactggcagcagccactggttaacaggattagcagcgg

4306 aggtatgtagcgggtgctacagagttcttgaagtggggcctaactacggctacactagaagaacagatttggatctgctgctctgtgaagccagttaccttc

4411 ggaaaaagagttggtagctctttagatccggcaaaacacaccgctggtagcgggtgttttttggttgcaagcagcagattacgcccagaaaaaaaggatctcaa

4516 gaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttgtcatgagattatcaaaaagatcttccacctagatc

4621 cttttaattaaaaatgaagttttaaataaatctaaagtatatatgagtaaacttggctgacagttaccaatgcttaatacagtgaggcacctatctcagcgatc

4726 tgtctatttcgcttccatagattgctgactccccgctgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataaccgctgac

AseI (4932)

4831 ccacgctcaccggctccagatttatcagcaataaacagccagccggaagcggcagcagaagtggtcctgcaactttatccgctccatccagctctattaat

AviII (4982)

4936 tgttgccgggaagctagagtaagtagttccagttaatagtttgcgcaacgttggccattgctacaggcatcgtggtgcaacgctcgttggtagggct

PvuI (5130)

5041 tcattcagctccggttcccaacgatcaaggcaggttacatgatccccatggtgtgcaaaaaagcggtagctcctcggctcctccagctgttgcagaagtaag

5146 ttggcccgagtggtatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtaactcaaccaag

5251 tcattctgagaatagtgatgcgggcagcaggttctcttggccggcgtcaatccgggataataccgcccacatagcagaactttaaaagtgtcatcattgga

5356 aaogtcttctggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaaccactcgtgacccaactgatcttcagcatctttactttc

5461 accagcgttctgggtgagcaaaaacaggaaggcaaaatgcccaaaaaaggaataaagggcgacacggaatggtgaatactcatactcttctcttttcaatat

5566 tattgaagcattttatcagggttattgtctcatgagcggatcacatattgaaatgatttagaaaaataacaaaataggggttccgcccacattttccccgaaaagt

BglII (5680) MscI (5759)

5671 ccacctgaagatctatacattgaaatcaatattggcaattagccatattagtcattggttatatagcataaatcaatattggctattggccattgcatacgttga

Bsp1407I (5791)

5776 tctatatcataatagtacattttatttggctcatgtccaatatgaccgcat

*This product is subject to Antibody Design Labs Terms & Conditions of Sales available online at <http://www.abdesignlabs.com/terms/>.  
 © 2023 Antibody Design Labs. All rights reserved.*

**Antibody Design Labs**  
 Phone: 877-223-3104 (Toll Free)  
[www.abdesignlabs.com](http://www.abdesignlabs.com)  
 Email: [support@abdesignlabs.com](mailto:support@abdesignlabs.com)

